Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Direct Meds Expands Into Canada, Easing Access to Prescription Weight Loss Medications

A US-based company specializing in helping individuals navigate the complexities of starting prescription weight loss medications is expanding their service area to include Canada.

(PRUnderground) October 18th, 2024

Direct Meds seeks to simplify access to prescription weight loss medications for individuals desiring to lose weight. Their unique all-inclusive pricing eliminates financial surprises, while quick access to certified medical doctors and pharmacies shortens the time to see a doctor or receive a prescription. To date, Direct Meds has only provided this service for United States residents. However, recent approvals received by Direct Meds open the door to helping patients in Canada as well.

Because obesity is a growing health concern in many countries, demand for weight loss solutions that work is increasing. While prescription medications, including Ozempic® (Semaglutide) and Mounjaro® (Tirzepatide), were developed as treatments for individuals with Type II Diabetes, they have proven effective in helping individuals lose weight when combined with dietary changes and exercise. Unfortunately, for many who could benefit from an online prescription for weight loss medications, gaining access to them takes time and money. For others, the thought of regular injections is a roadblock. Direct Meds strives to remove these and other barriers.

“We regularly hear from individuals who want to lose weight for themselves, their family, or their health,” remarked Dr. Justin Hohl, Direct Meds Medical Director. “Maybe they have tried dieting or working out more and perhaps even lost some weight. They know they need to lose more, but they don’t know if medication is right for them. Most have a lot of questions, including how they can afford it. That’s where Direct Meds can help. We connect them with an experienced medical doctor who can answer their questions and help them determine the best path forward.”

Semaglutide and Tirzepatide are compounded generic prescriptions equivalent to the popular weight loss medications Ozempic and Mounjaro. They work by mimicking naturally occurring hormones in the body that control blood sugar. The medicines also slow digestion and suppress appetite, allowing those taking them to feel satiated while eating fewer calories.

“We are excited to begin helping individuals in Canada understand and access weight loss medications,” stated Hohl. “Our goal is to remove the surprises. We want every person to understand what to expect from prescription weight loss, including the pricing, the potential symptoms, and possible outcomes from the start. Building trust with every patient is vital to the success of their weight loss journey.”

Direct Meds maintains a LegitScript certification, ensuring patients that its network of pharmacies, doctors, and software meets its high standards of privacy and safety. To learn more about Direct Meds and how it helps individuals start their weight loss journey with Semaglutide or Tirzepatide, call (888) 696-7176 or visit www.Direct-Meds.com.

About Direct Meds

Direct Meds transforms how healthcare is delivered by making prescription weight loss treatments more accessible. They believe that everyone deserves effective, reliable, and medically supervised solutions to manage weight and improve overall health.

The post Direct Meds Expands Into Canada, Easing Access to Prescription Weight Loss Medications first appeared on

Press Contact

Name: Direct Meds
Phone: 1-855-736-6285
Email: Contact Us

Original Press Release.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.